Ryne Bio
Nicholas Manusos is Chief Executive Officer of Ryne Bio. Recently as President & CEO of Opsis Therapeutics he led the company through a $70MM upfront/funding Strategic R&D Alliance with Bayer-BlueRock Therapeutics, and as COO of Iota Biosciences resulting in a $300MM acquisition by Astellas. Previously held roles include COO of FUJIFILM Cellular Dynamics Inc. and their board observer seat at Century Therapeutics; as VP, Global Head of Business Development at Baxter International Inc.; as VP, Licensing & Business Development at Takeda Pharmaceuticals; and in executive positions at Abbott Laboratories. Nick received his MBA from Northwestern University, J.L. Kellogg Graduate School of Management and his BBA, Operations Management from University of Wisconsin.
This person is not in any teams
This person is not in any offices
Ryne Bio
Ryne Bio is a biotechnology company advancing off-the-shelf neuron replacement therapies as potent disease-modifying treatments for neurological disorders. To achieve this they leverage induced pluripotent stem cell (iPSC) technology, which enables precision manufacture of therapeutically relevant human neurons. Their lead program targeting Parkinson’s Disease is a cryopreserved iPSC dopamine neuron progenitor (RNDP-001) that can be reliably manufactured and delivered